TargetMol

Aviptadil Acetate

Product Code:
 
TAR-TP1016L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TP1016L-1mg1mg£138.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1016L-5mg5mg£213.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1016L-10mg10mg£303.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1016L-25mg25mg£463.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1016L-50mg50mg£621.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1016L-100mg100mg£849.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Avitadil acetate induces pulmonary vasodilation and inhibits the proliferation of vascular SMCs and platelet aggregation. Avitadil acetate can be used for research on pulmonary fibrosis, pulmonary hypertension (PAH), and respiratory failure caused by SARS-CoV-2.
CAS:
1444827-29-5
Formula:
C147H238N44O42S.C2H4O2
Molecular Weight:
3385.9
Pathway:
Microbiology/Virology; Endocrinology/Hormones
Purity:
1
SMILES:
HSDAVFTDNY TRLRKQMAVK KYLNSILN(acetate salt)
Target:
RAAS; SARS-CoV

References

Hu J , Xu Q , Mctiernan C , et al. Novel Targets of Drug Treatment for Pulmonary Hypertension[J]. American Journal of Cardiovascular Drugs, 2015, 15(4):225-234. Frye BC, Meiss F, von Bubnoff D, Zissel G, M?ller-Quernheim J. Vasoactive Intestinal Peptide in Checkpoint Inhibitor-Induced Pneumonitis. N Engl J Med. 2020;382(26):2573-2574. doi:10.1056/NEJMc2000343